News & Insights

2025 has been a whirlwind year for global health. In the United States, we've seen the integration of the US Agency for International Development (USAID) into the Department of State, transformation at the Department of Health and Human Services (HHS), and a complicated and prolonged budget process. Globally, we've seen setbacks and progress in HIV and malaria, an evolution at the World Health Organization (WHO), a multilateral win with the Pandemic Agreement adoption, and African partners stepping up to boost autonomy.As the year draws to a close, GHTC is reflecting on the innovations, policy shifts, and pivotal moments that defined 2025 and what they signal for the years to come.US global health leadership in transitionOn day one of his second term, President Donald Trump initiated an effort to realign US foreign assistance programs with the goal of making America safer, stronger, and more prosperous. This effort started with an overhaul of USAID, triggering a series of layoffs, stop-work orders that turned into award terminations, and withdrawals from multilateral partnerships, culminating in the agency’s official integration into the State Department on July 1.While this suspension and termination of USAID programs disrupted critical research projects and health services worldwide earlier this year, in September, the State Department unveiled the America First Global Health Strategy, which outlines a plan to reshape the US government’s global health programming, presenting opportunities for global health research and development (R&D).The new strategy centers multiyear bilateral agreements with countries while reducing ties with nongovernmental organizations and narrowing health focal areas. While critical questions remain on implementation—including on whether the agency still retains needed expertise and how it will coordinate with interagency technical partners like the US Centers for Disease Control and Prevention (CDC)—the strategy’s focus on integrating aid more directly into national health systems is a step forward in improving sustainability and self-reliance. The strategy also raises the exciting possibility that funds could be used to support “innovative, breakthrough technologies.”  Building on USAID’s successes and shortcomings in that space, the department has a clear opportunity to establish a centralized R&D fund—in complement to bilateral agreements—to invest in innovative tools that could leapfrog global health progress. Through collaboration with global health stakeholders and interagency partners, State could reshape US global health programs to continue to save lives; foster funding beyond US government resources, including through partner nations; and promote shared security and prosperity.Overhaul of US scientific and public health infrastructureThe United States has long been a leader in global health R&D and science more broadly, with American researchers, universities, companies, and patients benefiting. In 2025, sweeping changes at HHS reshaped America’s public health and research infrastructure. These far-reaching reforms aimed to advance administration priorities of promoting “gold standard science,” improving efficiency, transparency, and oversight and realigning investments to match administration objectives. At the National Institutes of Health (NIH) and CDC, these changes have included significant staff departures, among them seasoned leaders, and the appointment of many officials who were previously critics of these agencies. It has also included new policies to overhaul oversight of foreign awards and cap indirect costs, changes to longstanding vaccine guidance, and the terminations of numerous awards, including a wind-down of mRNA vaccine development activities. The speed and scale of these changes have raised concerns across the biomedical research and public health communities. While thoughtful reforms could yield benefits, experts warn that current actions risk driving US scientists abroad, disrupting promising clinical trials, weakening the pipeline of new tools, eroding trust in public health guidance, and weakening the structures that have sustained US scientific leadership. US budget swings and shutdowns2025 began with a race to fund the government, with President Trump signing the fiscal year 2025 budget into law in mid-March. While the budget maintained global health R&D-relevant funding lines at prior levels, it funded a government that now looked significantly different after sweeping layoffs and restructuring. Months later, the administration issued its budget request, proposing significant cuts and a restructuring of global health and research programs, reflecting far-reaching changes it had already begun to enact.In June, the administration proposed a request to rescind billions in funding for foreign aid. Though Senators stepped in to remove cuts to global programs for HIV/AIDS and several other health areas, the package ultimately became law, cancelling $500 million in previously appropriated global health funds and raising the possibility that this administration will continue to use rescissions as a tool to withdraw funding.  By late summer, Senate and House appropriators advanced interim funding bills that included higher-than-expected funding for global health and medical research, maintaining funding proposed for elimination by the administration. But then stalled negotiations triggered the longest-ever government shutdown, during which the administration implemented unprecedented furloughs and layoffs that affected critical staff at public health and health research agencies.While the shutdown ended on November 12, pushing the funding fight until January, and most associated layoffs were reversed, uncertainty about future funding for global health R&D persists, especially with a deeply divided Congress and the potential of further recissions.A year of setbacks and breakthroughs in HIV and malaria effortsGlobal HIV/AIDS and malaria efforts faced major setbacks in 2025 as declining US and international donor support has threatened decades of hard-fought progress. Funding cuts could lead to millions of additional HIV and malaria cases in the coming years and has already stalled promising research advancing new HIV and malaria tools.Amid these challenges, the June approval by the US Food and Drug Administration of lenacapavir, a twice-yearly injectable drug for HIV prevention, marked a major milestone and a reminder of the incredible progress possible through strong support for research. Developed by Gilead and supported by NIH-backed research, the drug offers an alternative to daily pills or bi-monthly injections, making prevention more accessible and easier to maintain. Global partners are stepping up to expand access, and Phase 3 trials of a once-yearly version are planned.In November, Medicines for Malaria Venture and Novartis shared Phase 3 trial results for GanLum, a new drug found to be highly effective at treating malaria, including drug-resistant cases, and capable of blocking disease transmission. Pending approval, it could help counter rising resistance to current treatments.Other notable R&D advances in 2025 also targeted the growing threat of antimicrobial resistance, including a Phase 3 trial for a novel antibiotic targeting a dangerous antibiotic-resistant pathogen, support for what could be the first-ever vaccine for Escherichia coli, and efforts to harness artificial intelligence to transform antibiotic discovery. These breakthroughs underscore the importance of sustained R&D investment and the efforts to ensure new tools reach those who need them.WHO restructures amid budget shortfallFacing a severe budget crisis and pressure from member states to reprioritize programs, WHO launched a sweeping overhaul in 2025, cutting staff, slashing its budget, and reorganizing core functions. At its February Executive Board meeting, member states approved a $1.1 billion budget reduction, leaving a remaining $1.7 billion shortfall for 2026 and 2027, despite a recent increase to membership dues and appeals for voluntary contributions.In late April, WHO announced a plan to halve its senior leadership team and consolidate departments. Infectious disease and climate and health programs remain relatively well-resourced, and merging several disease-specific initiatives into a new division could strengthen certain programs. However, neglected tropical diseases and health emergency preparedness and response programs face sharp cuts, while reductions in regional and in-house expert posts may weaken global lab and surveillance networks and delay critical guidance, raising concerns about WHO’s outbreak response capacity.One core R&D function spared from the worst cuts was WHO’s prequalification (PQ) program, which evaluates medical products to support regulatory approval and rollout in countries with less advanced regulatory authorities. The program has marked some important achievements this year, launching a new portal to improve transparency for developers, introducing a new streamlined review and guidance process for TB diagnostics, and prequalifying lenacapavir for HIV prevention through a compressed process completed in just 36 days. As WHO and the broader United Nations system grapple with financial strain and diminished donor support, questions remain about the capacity to deliver on their mandate. A major outbreak could test the limits of this leaner system.Pandemic Agreement provides hope in challenging year for multilateralismAt the World Health Assembly in May, delegates adopted the Pandemic Agreement, a milestone win for global health after three years of complex negotiations. However, consensus on a pathogen and access-benefit sharing system was not reached, requiring member states to return to the negotiating table to finalize an annex for adoption at next year’s assembly. Persistent disputes over the voluntary or legally binding nature of participation signal tough negotiations ahead.While the Pandemic Agreement is a huge win, pushback from key countries and declining pandemic preparedness investments raise concerns about global readiness. Annex negotiations and the 2026 United Nations High-Level Meeting on Pandemic Prevention, Preparedness, and Response will further test international unity on this crucial topic.Meanwhile, 2026 brought notable R&D advances to strengthen our defenses against pandemic threats. The Coalition for Epidemic Preparedness Innovations launched the first-ever adjuvant library of 25 immune-boosting substances to improve vaccine effectiveness and awarded $17.3 million for Phase 2 trials of a promising Nipah vaccine, among the first candidates targeting the priority virus to reach this critical stage. IAVI’s vaccine candidate for Lassa virus, another virus with pandemic potential, was also found to be safe and effective in a first-in-human Phase 1 trial, marking further R&D progress against concerning disease threats.Partners step up to fill gaps and boost autonomyAmid steep foreign aid funding losses, African nations are accelerating efforts to boost manufacturing and laboratory capacity on the continent and reduce reliance on external partners. At October’s Conference on Public Health in Africa in Durban, South Africa, thousands of participants endorsed The Durban Promise, a roadmap for Africa’s health sovereignty, urging action on manufacturing, financing, workforce and capacity development, and regulatory strengthening, a signal of growing continental unity.This momentum was echoed by the Accra Reset, led by Ghanaian President John Mahama, to forge further progress toward greater sovereignty and more equitable global cooperation. At the continental level, the Africa Centres for Disease Control and Prevention launched a new biomanufacturing fellowship to help meet the goal of producing 60 percent of Africa’s vaccine dose needs locally by 2040.South Africa held the G20 presidency this year, culminating in the first G20 summit held on African soil and a declaration focused on priorities for Africa and the Global South. The summit was punctuated by the absence of the United States, underscoring the imperative for greater African autonomy as international aid declines and health threats rise. With the United States assuming the G20 presidency next year, its priorities will be closely watched. Looking ahead to 2026If 2025 has taught us anything, it’s that global health is unpredictable and constantly evolving, so we won’t speculate on exactly what 2026 may bring. But a truth remains clear: global health R&D is a strong investment that pays off—saving lives, strengthening economies, and fueling scientific progress. As the United States redefines its approach and role in the broader global health ecosystem, it remains to be seen how it, and others, will step up to ensure that promising technologies in the pipeline are advanced to improve lives around the world.For other fascinating global health news delivered to your inbox weekly and to stay abreast of developments in 2026 and beyond, sign up now to receive GHTC’s R&D News Roundup newsletter.

A study, led by the Global Antibiotic Research and Development Partnership, testing zoliflodacin, found that the antibiotic was as effective and tolerable as the standard treatment for gonorrhea and was effective against drug-resistant strains of the bacteria, as resistance continues to rise globally. Injectable ceftriaxone is our last remaining antibiotic that works against most strains of Neisseria gonorrhoeae; however, we are already seeing evidence of evolving resistance, underscoring the urgent need for new antibiotic options to treat drug-resistant cases. If approved by the US Food and Drug Administration, which is expected to make a decision soon, zoliflodacin could be used as both a first-line treatment and a last-resort option after standard treatments fail due to drug resistance.An international team of researchers has made the first major step toward a new and improved vaccine or antibody therapy to address mpox, a dangerous virus that has been behind worrying outbreaks that have emerged around the world. Using the blood of patients with previous infection or vaccination, researchers identified 12 antibodies that could clear the virus. Then, another research team used artificial intelligence (AI) to pinpoint what part of the virus acted as an antigen for those antibodies—a process that could have taken years without the use of AI—and then engineered an antigen to elicit similar antibodies in mice, which produced antibodies that neutralized the virus when injected with it. The researchers are now working to develop versions of the vaccine antigen and antibodies that are more effective at fighting disease and also cheaper and easier to produce than existing products that use a weakened version of the related poxvirus. The Korean Disease Control Agency, the International Vaccine Institute (IVI), ST Pharm, and Seoul National University are partnering with the Coalition for Epidemic Preparedness Innovations (CEPI) to advance a new mRNA vaccine against a deadly emerging virus, which was designed with the use of AI. Cases of the tick-borne thrombocytopaenia syndrome, or SFTS, have been reported in five Asian countries and cause severe symptoms and, in several cases, death. IVI will advance the vaccine candidate into preclinical and Phase 1 and 2 clinical trials in Korea, the first time a candidate for the virus would be tested in humans. STFS virus is also part of the Phenuivirus family; a successful vaccine against this virus could advance work to develop vaccines against other closely related viruses with pandemic potential. 

The Sabin Vaccine Institute has sent more than 640 doses of its investigational Marburg vaccine to Ethiopia, as the country continues to battle its first-ever outbreak of Marburg, a highly contagious and fatal disease for which there are currently no available vaccines or treatments. Soon after the outbreak was confirmed to be Marburg, Ethiopian authorities coordinated with Sabin and the Biomedical Advanced Research and Development Authority, which is supporting development of the vaccine candidate, to obtain access to doses for an outbreak trial. Sabin and the Ethiopian Ministry of Health have signed a clinical trial agreement under which Sabin is providing doses for a two-cohort Phase 2 open-label trial, involving health care and frontline workers, as well as direct contacts of people with confirmed infections. The vaccine is also being tested in Phase 2 clinical trials in Rwanda, the United States, Uganda, and Kenya, which will hopefully yield evidence to support its continued development and use as a tool in future outbreaks. The Oxford Vaccine Group has vaccinated the first volunteer in a first-in-human trial of its vaccine for Lassa fever, which is caused by Lassa virus, a deadly virus with significant epidemic potential. The trial, funded by CEPI, is being conducted among 31 people between 18 and 51 in Oxford, England, with a second Phase 1 trial in Ghana set to start in early 2026. The vaccine was developed by researchers at the Pandemic Sciences Institute at the University of Oxford and uses the same viral vector platform as the Oxford/AstraZeneca COVID-19 vaccine. The Lassa fever Coalition, led by the West African Health Organization, with support from CEPI and partners, is already working with vaccine developers to accelerate the development and equitable introduction of future vaccines across the West African region, which faces a significant burden of Lassa fever. A Penn State research team has developed a new rapid test that can differentiate active HIV from false positives, which could potentially accelerate the development of a vaccine for HIV. HIV vaccines in development are designed to trigger the body to produce antibodies that target key proteins on the virus’s surface. However, these proteins are also what diagnostic tests detect to confirm an infection, leading trial participants to falsely test positive for HIV, complicating diagnosis and clinical management. Researchers have to use timely and expensive multistep diagnostic procedures to distinguish between those with actual infections and these false positives. The Penn State researchers partnered with the HIV Vaccine Trials Network to test human blood samples with the new testing device, finding that it was highly effective at distinguishing between active infections and false positives and generated results in just five minutes.